Abstract
Subcutaneous interferon beta 1a (IFN β 1a) has been shown to reduce relapse rates in patients with relapsing-remitting
multiple sclerosis. We report the occurrence of severe necrotizing cutaneous reactions in a 19-year-old girl. She self
injected IFN β 1a three times a week on the abdomen and both thighs. Treatment was initially well tolerated, but she
described erythematous patches and local pain at the injection sites recently. The areas on the abdomen became
violaceous with necrotic ulcers. Her therapy was changed to 0.5 mg fingolimod. The lesions began to improve and
cicatrize after several weeks with postinflammatory hyperpigmentation. Early recognition of severe local adverse
reactions and correction of the injection technique is important.
Keywords: Interferon beta 1a
References
- 1. PRISMS (Prevention of Relapses and Disability by Interferon betala
- Subcutaneously in Multiple sclerosis) Study Group. Randomized
- double-blind placebo-controlled study of interferon beta-la in
- relapsing-remitting multiple sclerosis. Lancet 1998;352:1498-504.
- 2. Elgart GW, Sheremata W, Ahn YS. Cutaneous reactions to
- recombinant human interferon beta 1b: The clinical and histologic
- spectrum. J Am Acad Dermatol 1997;37:5538.
- 3. Lebrun C, Bertagna M, Cohen M. Cutanous side effects of
- immunomodulators in MS. Int MS J 2011;17:88-94.
- 4. Beer K, Müller M, Hew-Winzeler AM, Bont A, Maire P, You X, et al.
- The prevalence of injection-site reactions with disease-modifying
- therapies and their effect on adherence in patients with multiple
- sclerosis: An observational study. BMC Neurol 2011;11:144.
- 5. Sheremata WA, Taylor JR, Elgart GW. Severe necrotizing cutaneous
- lesions complicating treatment with interferon beta-1b. N Engl J
- Med 1995;332:1584.
